{"created":"2023-05-15T16:50:05.279868+00:00","id":27803,"links":{},"metadata":{"_buckets":{"deposit":"2b5fe9d1-7d8b-4bd6-a1fd-e062fa583a57"},"_deposit":{"created_by":6,"id":"27803","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"27803"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00027803","sets":["10:11"]},"author_link":["123722","123727","123728","123737","123735","123721","123720","123724","123723","123734","123731","123732","123736","123730","123733","123725","123726","123729"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-12-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"264","bibliographicVolumeNumber":"24","bibliographic_titles":[{"bibliographic_title":"Arthritis Research & Therapy"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: This exploratory study compared the inhibition of bone erosion progression in rheumatoid arthritis (RA) patients treated with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab versus csDMARD therapy alone and investigated the effects of denosumab on bone micro-architecture and other bone-related parameters using high-resolution peripheral quantitative computed tomography (HR-pQCT).\nMethods: In this open-label, randomized, parallel-group study, patients with RA undergoing treatment with a csDMARD were randomly assigned (1:1) to continue csDMARD therapy alone or to continue csDMARDs with denosumab (60-mg subcutaneous injection once every 6 months) for 12 months. The primary endpoint was the change from baseline in the depth of bone erosion, measured by HR-pQCT, in the second and third metacarpal heads at 6 months after starting treatment. Exploratory endpoints were also evaluated, and adverse events (AEs) were monitored for safety.\nResults: In total, 46 patients were enrolled, and 43 were included in the full analysis set (csDMARDs plus denosumab, N = 21; csDMARD therapy alone, N = 22). Most patients were female (88.4%), and the mean age was 65.3 years. The adjusted mean (95% confidence interval) change from baseline in the depth of bone erosion, measured by HR-pQCT, in the 2–3 metacarpal heads at 6 months was − 0.57 mm (− 1.52, 0.39 mm) in the csDMARDs plus denosumab group vs − 0.22 mm (− 0.97, 0.53 mm) in the csDMARD therapy alone group (between-group difference: − 0.35 mm [− 1.00, 0.31]; P = 0.2716). Similar results were shown for the adjusted mean between-group difference in the width and volume of bone erosion of the 2–3 metacarpal heads. Significant improvements in bone micro-architecture parameters were shown. The incidence of AEs and serious AEs was similar between the csDMARDs plus denosumab and the csDMARD therapy alone groups (AEs: 52.2% vs 56.5%; serious AEs: 4.3% vs 8.7%).\nConclusions: Although the addition of denosumab to csDMARDs did not find statistically significant improvements in bone erosion after 6 months of treatment, numerical improvements in these parameters suggest that the addition of denosumab to csDMARDs may be effective in inhibiting the progression of bone erosion and improving bone micro-architecture.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Arthritis Research and Therapy, 24(1), art. no. 264; 2022","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BMC"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/s13075-022-02957-w","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1478-6362","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Iwamoto, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Chiba, Ko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sato, Shuntaro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shiraishi, Kazuteru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Watanabe, Kounosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oki, Nozomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okada, Akitomo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koga, Tomohiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawashiri, Shin-ya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tamai, Mami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hosogaya, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Furuyama, Masako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kobayashi, Makiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saito, Kengo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okubo, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uetani, Masataka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Osaki, Makoto"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-12-19"}],"displaytype":"detail","filename":"ART24_264.pdf","filesize":[{"value":"894.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ART24_264.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/27803/files/ART24_264.pdf"},"version_id":"accd6262-c41c-48b2-bb12-d4cc591d16b1"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Bone erosion","subitem_subject_scheme":"Other"},{"subitem_subject":"csDMARDs","subitem_subject_scheme":"Other"},{"subitem_subject":"Denosumab","subitem_subject_scheme":"Other"},{"subitem_subject":"HR-pQCT","subitem_subject_scheme":"Other"},{"subitem_subject":"Rheumatoid arthritis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study"}]},"item_type_id":"2","owner":"6","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-12-19"},"publish_date":"2022-12-19","publish_status":"0","recid":"27803","relation_version_is_last":true,"title":["Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T19:09:13.143466+00:00"}